keyword
MENU ▼
Read by QxMD icon Read
search

pneumococcal conjugate vaccine

keyword
https://www.readbyqxmd.com/read/29330244/primary-care-physicians-struggle-with-current-adult-pneumococcal-vaccine-recommendations
#1
Laura P Hurley, Mandy A Allison, Tamara Pilishvili, Sean T O'Leary, Lori A Crane, Michaela Brtnikova, Brenda L Beaty, Megan C Lindley, Carolyn B Bridges, Allison Kempe
INTRODUCTION: In 2012, the Advisory Committee on Immunization Practices recommended 13-valent pneumococcal conjugate vaccine (PCV13) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for at-risk adults ≥19; in 2014, it expanded this recommendation to adults ≥65. Primary care physicians' practice, knowledge, attitudes, and beliefs regarding these recommendations are unknown. METHODS: Primary care physicians throughout the U.S. were surveyed by E-mail and post from December 2015 to January 2016...
January 2018: Journal of the American Board of Family Medicine: JABFM
https://www.readbyqxmd.com/read/29329169/differences-in-immunization-site-pain-in-toddlers-vaccinated-with-either-the-10-or-the-13-valent-pneumococcal-conjugate-vaccine
#2
Johannes Trück, Sarah Kelly, Sena Jawad, Matthew D Snape, Merryn Voysey, Andrew J Pollard
We investigated immediate immunization pain in 12-month-old children randomized to receive a booster dose of either the 10- (PCV-10) or the 13-valent (PCV-13) pneumococcal conjugate vaccine. Pain was assessed using validated pain assessment tools and crying time. PCV-13 recipients had significantly higher scores on the observer-rated modified behavioral pain scale than did those receiving PCV-10, but the differences were small.Clinical trial registration at Clinicaltrials.gov (NCT01443416).
January 10, 2018: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29325173/immunogenicity-and-safety-of-pneumococcal-vaccination-in-patients-with-systemic-sclerosis
#3
Roger Hesselstrand, Johanna Nagel, Tore Saxne, Pierra Geborek, Lillemor Skattum, Meliha C Kapetanovic
Objective: To study the impact of disease and treatment with DMARDs on antibody response elicited by either pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23) in patients with SSc. Methods: Forty-four SSc patients and 49 controls received a dose of either PCV13 or PPV23. Twelve patients were treated with DMARDs. Antibody levels to pneumococcal polysaccharides 6B and 23 F were measured before and 4-6 weeks after vaccination using ELISA...
January 8, 2018: Rheumatology
https://www.readbyqxmd.com/read/29324986/the-impact-of-the-13-valent-pneumococcal-conjugate-vaccine-on-pneumococcal-carriage-in-the-community-acquired-pneumonia-immunization-trial-in-adults-capita-study
#4
Anna M M van Deursen, Marlies A van Houten, Chris Webber, Michael Patton, Daniel Scott, Scott Patterson, Qin Jiang, William C Gruber, Beate Schmoele-Thoma, Diederick E Grobbee, Marc J M Bonten, Elisabeth A M Sanders
Background: The impact of pneumococcal conjugate vaccination on the prevalence of nasopharyngeal carriage with pneumococci and other bacteria in adults is unknown. The direct effects of the 13-valent pneumococcal conjugate vaccine (PCV13) in community dwelling older adults was investigated as part of the randomized controlled Community Acquired Pneumonia immunization Trial in Adults (CAPiTA). Methods: We determined the carriage of S. pneumoniae, S. aureus, H. influenzae, and M...
January 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29318106/pneumococcal-vaccination-in-older-persons-where-are-we-today
#5
REVIEW
Paul Van Buynder, Robert Booy
Disease due to Streptococcus pneumoniae, the pneumococcus, remains a major source of illness in older persons. Globally, it remains the most important pathogen in respiratory infection deaths. Conjugated pneumococcal vaccines are used extensively in national pediatric programs, whereas a polysaccharide vaccine is used in all age groups, but mainly in the elderly and for high-risk groups. Recent data from the Netherlands led to the licensing in many countries of conjugated pneumococcal vaccines for older persons...
2018: Pneumonia
https://www.readbyqxmd.com/read/29317512/streptococcus-pneumoniae-modulates-staphylococcus-aureus-biofilm-dispersion-and-the-transition-from-colonization-to-invasive-disease
#6
Ryan M Reddinger, Nicole R Luke-Marshall, Shauna L Sauberan, Anders P Hakansson, Anthony A Campagnari
Streptococcus pneumoniae and Staphylococcus aureus are ubiquitous upper respiratory opportunistic pathogens. Individually, these Gram-positive microbes are two of the most common causative agents of secondary bacterial pneumonia following influenza A virus infection, and they constitute a significant source of morbidity and mortality. Since the introduction of the pneumococcal conjugate vaccine, rates of cocolonization with both of these bacterial species have increased, despite the traditional view that they are antagonistic and mutually exclusive...
January 9, 2018: MBio
https://www.readbyqxmd.com/read/29313476/serotype-distribution-of-clinical-streptococcus-pneumoniae-isolates-before-the-introduction-of-the-13-valent-pneumococcal-conjugate-vaccine-in-cambodia
#7
Malin Inghammar, Youlet By, Christina Farris, Thong Phe, Laurence Borand, Alexandra Kerleguer, Sophie Goyet, Vonthanak Saphonn, Chanleakhena Phoeung, Sirenda Vong, Blandine Rammaert, Charles Mayaud, Bertrand Guillard, Chadwick Yasuda, Matthew R Kasper, Gavin Ford, Steven W Newell, Ung Sam An, Buth Sokhal, Sok Touch, Paul Turner, Jan Jacobs, Mélina Messaoudi, Florence Komurian-Pradel, Arnaud Tarantola
Childhood vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in Cambodia in January 2015. Baseline data regarding circulating serotypes are scarce. All microbiology laboratories in Cambodia were contacted for identification of stored isolates of Streptococcus pneumoniae from clinical specimens taken before the introduction of PCV13. Available isolates were serotyped using a multiplex polymerase chain reaction method. Among 166 identified isolates available for serotyping from patients with pneumococcal disease, 4% were isolated from upper respiratory samples and 80% were from lower respiratory samples, and 16% were invasive isolates...
January 8, 2018: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29304066/burden-of-invasive-pneumococcal-disease-among-children-in-rural-mozambique-2001-2012
#8
Betuel Sigaúque, Jennifer R Verani, Sérgio Massora, Delfino Vubil, Llorenç Quintó, Sozinho Acácio, Inácio Mandomando, Quique Bassat, Tacilta Nhampossa, Fabiana Pimenta, Charfudin Sacoor, Maria da Gloria Carvalho, Eusebio Macete, Pedro L Alonso
BACKGROUND: Invasive pneumococcal disease (IPD) is a major cause of illness and death among children worldwide. 10-valent pneumococcal conjugate vaccine (PCV10) was introduced as part of the Mozambican routine immunization program in April 2013. We characterized the IPD burden in a rural area of Mozambique before PCV introduction and estimated the potential impact of this intervention. METHODS: We conducted population-based surveillance for IPD, defined as S. pneumoniae isolated from blood or cerebrospinal fluid, among children <5 years old admitted to Manhiça District Hospital, a referral hospital in a rural area with high prevalence of human immunodiciency virus infection...
2018: PloS One
https://www.readbyqxmd.com/read/29290234/bacterial-meningitis-antibiotic-treatment
#9
R Cohen, J Raymond, L Hees, D Pinquier, E Grimprel, C Levy
The implementation of pneumococal conjugate vaccines (PCVs) 7 then 13 valent (Prevenar13®) in 2010-2011 has significantly changed the profile of pneumococcal meningitis. Since 3 years, the National Pediatric Meningitis Network of the Pediatric Infectious Disease Group (GPIP) and the National Reference Centre of Pneumococci have reported no cases of meningitis due to pneumococcus resistant to third-generation cephalosporins (3GC): cefotaxime or ceftriaxone. In the light of these new data, vancomycin should no longer be prescribed at the initial phase of pneumococcal meningitis treatment (confirmed or only suspected) and this antibiotic should only be added when 3GC minimum inhibitory concentration of the strain isolated is greater than 0...
December 2017: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/29290229/antibiotic-treatment-of-lower-respiratory-tract-infections
#10
R Cohen, F Angoulvant, S Biscardi, F Madhi, F Dubos, Y Gillet
Lower respiratory tract infections, i.e., bronchitis, bronchiolitis, and pneumonia, are the second leading cause of antibiotic prescriptions. The vast majority of these infections are due to viruses and are self-limited diseases: most patients recover spontaneously. These two facts explain that antibiotic prescriptions must be limited to some clinical situations for which the diagnosis has to be done early. The first message of this manuscript is to strengthen non-antibiotic prescriptions in many situations such as bronchitis and bronchiolitis...
December 2017: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/29289385/phenotypic-and-molecular-characterization-of-streptococcus-pneumoniae-in-pre-conjugate-vaccine-era-a-chinese-hospital-based-retrospective-study
#11
Ling Li, Jinjian Fu, Shunming Li, Dan Guo, Zhiyao Chen, Sidong Chen, Xiaohua Ye
BACKGROUND: Streptococcus pneumoniae (S. pneumoniae) is an important pathogen in causing global morbidity and mortality among children. This study aimed to determine phenotypic and molecular characteristics of S. pneumoniae causing infections in children under five years in China. METHODS: A hospital-based retrospective study was conducted. All 537 S. pneumoniae isolates were tested for antimicrobial susceptibility by E-test method, molecular characteristics including resistance genes, virulence genes and serotypes by multiplex polymerase chain reaction (PCR) method, and sequence types (STs) by sequencing seven housekeeping genes...
December 27, 2017: Vaccine
https://www.readbyqxmd.com/read/29287882/changes-in-the-epidemiology-and-clinical-features-of-acute-mastoiditis-following-the-introduction-of-the-pneumococcal-conjugate-vaccine
#12
Oren Cavel, Riva Tauman, Eli Simsolo, Danny Yafit, Efrat Reindorf-Kfir, Oshri Wasserzug, Omer Unger, Ophir Handzel, Gadi Fishman, Yael Oestreicher-Kedem, Ari DeRowe
OBJECTIVES: Seven years after the introduction of the pneumococcal conjugate vaccines (PCV) in Israel, its effect on the incidence and severity of episodes of acute mastoiditis (AM) remains unclear. The primary objective of this study was to determine the incidence of AM and describe its clinical features in children during the years that followed the introduction of the PCV13 in comparison with the pre-PCV period. METHODS: Included in this retrospective comparative case series were all pediatric patients diagnosed with AM between Jan...
January 2018: International Journal of Pediatric Otorhinolaryngology
https://www.readbyqxmd.com/read/29284419/serotype-distribution-and-antibiotic-resistance-of-streptococcus-pneumoniae-isolates-from-17-chinese-cities-from-2011-to-2016
#13
Chunjiang Zhao, Zongbo Li, Feifei Zhang, Xiaobing Zhang, Ping Ji, Ji Zeng, Bijie Hu, Zhidong Hu, Kang Liao, Hongli Sun, Rong Zhang, Bin Cao, Chao Zhuo, Wei Jia, Yaning Mei, Yunzhuo Chu, Xuesong Xu, Qing Yang, Yan Jin, Quan Fu, Xiuli Xu, Hongling Li, Lijun Wang, Yuxing Ni, Hongjie Liang, Hui Wang
BACKGROUND: Streptococcus pneumoniae, the leading pathogen of bacterial infections in infants and the elderly, is responsible for pneumococcal diseases with severe morbidity and mortality. Emergence of drug-resistant strains presented new challenges for treatment and prevention. Vaccination has proven to be an effective means of preventing pneumococcal infection worldwide. Detailed epidemiological information of antibiotic susceptibilities and serotype distribution will be of great help to the management of pneumococcal infections...
December 29, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29282225/risk-of-invasive-pneumococcal-disease-in-children-with-sickle-cell-disease-in-england-a-national-observational-cohort-study-2010-2015
#14
Godwin Oligbu, Sarah Collins, Carmen Sheppard, Norman Fry, Moira Dick, Allison Streetly, Shamez Ladhani
OBJECTIVE: To describe the clinical presentation, risk factors, serotype distribution and outcomes of invasive pneumococcal disease (IPD) in children with sickle cell disease (SCD) following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in the UK. DESIGN: Prospective national newborn screening for SCD and enhanced national IPD surveillance. PARTICIPANTS: Children with SCD born in England between 1 September 2010 and 31 August 2014 who developed laboratory-confirmed IPD by 31 December 2015...
December 27, 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/29279284/re-emergence-of-pneumococcal-colonization-by-vaccine-serotype-19f-in-persons-aged-%C3%A2-5-years-after-13-valent-pneumococcal-conjugate-vaccine-introduction-alaska-2008-2013
#15
Prabhu P Gounder, Dana Bruden, Karen Rudolph, Tammy Zulz, Debby Hurlburt, Gail Thompson, Michael G Bruce, Thomas W Hennessy
BACKGROUND: The pneumococcal conjugate vaccine (PCV) was introduced in 2001. Widespread PCV use nearly eradicated pneumococcal colonization by vaccine serotypes. Since 2008, however, colonization by PCV-serotype 19F has increased in Alaska residents. We describe the epidemiology of re-emerging serotype 19F colonization. METHODS: We conducted annual cross-sectional colonization surveys from 2008 to 2013. We recruited children aged <5 years at 2 urban clinics and participants of all ages from Region-A (2 villages), Region-B (4 villages), and Region-C (2 villages)...
December 23, 2017: Vaccine
https://www.readbyqxmd.com/read/29279281/randomized-clinical-trial-of-a-single-versus-a-double-dose-of-13-valent-pneumococcal-conjugate-vaccine-in-adults-55-through-74%C3%A2-years-of-age-previously-vaccinated-with-23-valent-pneumococcal-polysaccharide-vaccine
#16
Lisa A Jackson, Hana M El Sahly, Sarah George, Patricia Winokur, Kathryn Edwards, Rebecca C Brady, Nadine Rouphael, Wendy A Keitel, Mark J Mulligan, Robert L Burton, Aya Nakamura, Jennifer Ferreria, Moon H Nahm
INTRODUCTION: In older adults, prior administration of 23-valent pneumococcal polysaccharide vaccine (PPSV23) blunts the opsonophagocytic antibody (OPA) response to subsequent administration of 13-valent pneumococcal conjugate vaccine (PCV13). To determine whether a higher dose of PCV13 could mitigate this effect in adults 55 through 74 years of age, we compared OPA responses to a double dose of PCV13 in persons previously vaccinated with PPSV23 with responses to a single dose of PCV13 in previously vaccinated persons, and with a single dose in PPSV23 naïve persons...
December 23, 2017: Vaccine
https://www.readbyqxmd.com/read/29278616/decreased-aom-with-treatment-failure-following-introduction-of-the-ten-valent-pneumococcal-haemophilus-influenzae-protein-d-conjugate-vaccine
#17
Elias Eythorsson, Birgir Hrafnkelsson, Helga Erlendsdóttir, Sigmar Atli Gudmundsson, Karl G Kristinsson, Ásgeir Haraldsson
BACKGROUND: Acute otitis media non-responsive to antibiotics is most commonly caused by antibiotic-resistant Streptococcus pneumoniae and Haemophilus influenzae. A strategy for treating these infections with parenteral ceftriaxone was adopted at The Children's Hospital Iceland. The 10-valent pneumococcal H. influenzae Protein D-conjugate vaccine (PHiD-CV10) was introduced into the vaccination program in Iceland in 2011. The aim was to study its effect on the incidence of AOM with treatment failure...
December 22, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29277353/immunologic-non-inferiority-and-safety-of-the-investigational-pneumococcal-non-typeable-haemophilus-influenzae-protein-d-conjugate-vaccine-phid-cv-4-dose-vial-presentation-compared-to-the-licensed-phid-cv-1-dose-vial-presentation-in-infants-a-phase-iii-randomized
#18
Khalequ Zaman, Sheikh Farzana Zaman, Farzana Zaman, Asma Aziz, Sayeed-Bin Faisal, Magali Traskine, Md Ahsan Habib, Javier Ruiz-Guiñazú, Dorota Borys
BACKGROUND: To support vaccination programs in developing countries, a 4-dose vial presentation of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was developed. This study assessed immunologic non-inferiority and safety of the investigational PHiD-CV 4-dose versus licensed 1-dose vial presentation in infants. METHODS: In this phase III, mono-center, observer-blind study in Bangladesh, 6-10-week-old infants were randomized 1:1 to receive PHiD-CV primary vaccination (at ages 6, 10, 18 weeks) and a booster dose (at age 9 months) with a 4-dose vial (with preservative, 4DV group) or 1-dose vial (preservative-free, 1DV group)...
December 22, 2017: Vaccine
https://www.readbyqxmd.com/read/29261406/effectiveness-and-practical-uses-of-23-valent-pneumococcal-polysaccharide-vaccine-in-healthy-and-special-populations
#19
Yang Wang, Jingxin Li, Yuxiao Wang, Wei Gu, Fengcai Zhu
Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people ≥ 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults...
December 20, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29258705/invasive-pneumococcal-disease-in-children-under-16%C3%A2-years-of-age-incomplete-rebound-in-incidence-after-the-maximum-effect-of-pcv13-in-2012-13-in-germany
#20
Raphael Weinberger, Rüdiger von Kries, Mark van der Linden, Thorsten Rieck, Anette Siedler, Gerhard Falkenhorst
OBJECTIVE: To identify a potential nadir of the impact of pneumococcal conjugate vaccination (PCV) in infancy on invasive pneumococcal diseases (IPD) in children under 16 in Germany. METHODS: Active surveillance on IPD based on two independent data sources with capture-recapture correction for underreporting. Annual incidence rates by age group, serotypes, site of infection, and relative incidence reduction compared to pre-vaccination period (1997-2001) at nadir and for the most recent season are reported...
December 16, 2017: Vaccine
keyword
keyword
112012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"